-去背.png){kind=logo}
Taipei, Taiwan — 28 May 2026
TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”) and QIMR Berghofer Medical Research Institute (Headquarters: Herston, Queensland, Australia; hereinafter “QIMR Berghofer”) jointly announced the signing of a Memorandum of Understanding (MOU) on April 29, 2026, establishing a strategic partnership in the field of cell and gene therapy (CGT). The collaboration aims to combine the expertise and resources of both organizations to advance the development of innovative therapies and expand international market opportunities.
QIMR Berghofer is a leading translational medical research institute based in Brisbane, Australia. Its state-of-the-art facilities include Q-Gen Cell Therapeutics, which has been at the forefront of manufacturing cell therapies for more than 25 years. QIMR Berghofer is dedicated to advancing innovative therapies from basic research and preclinical development through to early-stage clinical application.
TFBS Bioscience specializes in viral vector manufacturing and provides integrated services for cell and gene therapies, vaccines, and biologics, spanning research and development, process development, GMP manufacturing, as well as biosafety, preclinical, and clinical-related testing services.
In addition, both parties will enhance global market visibility and strengthen their presence in the Asia-Pacific region through joint participation in international industry events and resource integration. This cross-border collaboration is expected to bridge industry and research capabilities, accelerating the translation and clinical application of cell and gene therapy technologies.
Signing Ceremony: From left: Dr. Tatung Yuan (Chairman and CEO, TFBS Bioscience), Dr. Robert McLachlan (Chief Commercial Officer, QIMR Berghofer)
About QIMR Berghofer
QIMR Berghofer is a world-leading, translational medical research institute committed to delivering scientific excellence and driving innovation in human health. Established in 1945, the Institute is home to almost 1,000 scientists, clinician-scientists, support staff, and students working across four key research programs of Cancer Research, Infection and Inflammation, Population Health, and Brain and Mental Health. Its state-of-the-art facilities include Q-Gen Cell Therapeutics, which manufactures cell therapies. QIMR Berghofer seeks to deliver better health and wellbeing through impactful medical research that responds to the foremost health challenges of our time.
For more information head to qimrb.edu.au.
About TFBS Bioscience Inc.
TFBS Bioscience Inc. (TFBS) was founded in 2016 as the first contract research organization providing biological testing in Taiwan after its spin-off from Development Center for Biotechnology, a government-sponsored research institute. TFBS has established strong track records in several regulatory submissions, winning trust from the international regulatory agencies and biopharmaceutical industry. TFBS has launched the first viral vector contract development and manufacturing facility in Taiwan, providing fully integrated end-to-end contract development and manufacturing services for the needs of clinical trials. TFBS offers manufacturing expertise in adeno-associated virus, lentivirus, and retrovirus. With the customization specialty and state-of-the-art facility, TFBS is the best partner offering clients a one-stop-shop solution for gene and cell therapy.
For more information, please visit www.tfbsbio.com.
Contact Information for This Matter:
TFBS Bioscience, Inc.
Email: service@tfbsbio.com
QIMR Berghofer
Email: media@qimrb.edu.au